On a visit through London today, NodThera's CEO Dan Swisher discusses the company's brain-penetrant NLRP3 platform, including an asset that's in phase 2 for weight loss

He discusses the science behind NLRP3, and describes why he thinks NodThera's brain penetration differentiates it from other programs from pharma and other companies. The weight loss program is a oral therapy that doesn't require titration and hasn't shown GI tolerability side effects.